Vaccination Remains Key to Preventing Meningococcal Meningitis, Experts Say

Following a recent outbreak of meningitis B in Kent, United Kingdom, health experts are reinforcing the importance of vaccination as the most effective measure against meningococcal meningitis. Although outbreaks are typically localized and controllable, vigilance and preventative measures remain crucial.

Understanding Meningococcal Meningitis

Meningococcal disease, including serogroup B, is a serious infection caused by the bacterium Neisseria meningitidis, commonly known as meningococcus. Transmission occurs through respiratory droplets or saliva, generally requiring close and prolonged contact such as kissing, coughing nearby, or sharing personal items like glasses.

Symptoms of meningococcal meningitis can appear rapidly and include:

• High fever
• Neck stiffness
• Severe headache
• Sensitivity to light
• Nausea
• Confusion
• A petechial or purpuric rash (purple spots on the skin)

The infection can progress quickly and is potentially fatal, even with treatment. Mortality rates are approximately 10 percent, and up to 20 percent of survivors may experience lasting sequelae such as deafness or brain damage.

Who is at Risk?

In Europe, the most vulnerable age groups include infants under one year ancient, young children between one and four years old, and adolescents and young adults aged 15 to 24.

Immediate Action in Suspected Cases

If meningococcal disease is suspected, immediate action is critical. Individuals showing symptoms should be isolated, and broad-spectrum antibiotics should be administered without delay, even before microbiological confirmation. Once a diagnosis is confirmed, antibiotics can be adjusted based on bacterial sensitivity testing. Corticosteroids are similarly recommended to reduce the risk of neurological complications.

Close contacts – including household members, those exposed to oral secretions, and individuals in daycare or residential settings – should receive preventative antibiotic treatment as soon as possible and be vaccinated against meningococcus if appropriate.

Vaccination Schedules in Spain

The vaccine against meningococcus B has been included in Spain’s childhood vaccination schedule since the end of 2022, administered at two, four, and 12 months of age. The vaccine against meningococcus C is also given at four and 12 months. Vaccination against meningococcal A, C, W, and Y is administered at 12 years of age, with a catch-up vaccination program for unvaccinated adolescents up to 18 years of age.

The Vaccine Advisory Committee and the Spanish Association of Pediatrics recommend systematic vaccination against meningococcus B for adolescents at 12 years old to reinforce protection against unpredictable outbreaks, which are increasing in nearby countries. For those over 12, vaccination is recommended on an individualized basis.

Disclaimer: This article provides general information and should not be considered medical advice. Always consult with a healthcare professional for any health-related concerns.